RESUMEN
Sulfite intoxication is the hallmark of four ultrarare disorders that are caused by impaired sulfite oxidase activity due to genetic defects in the synthesis of the molybdenum cofactor or of the apoenzyme sulfite oxidase. Delays on the diagnosis of these disorders are common and have been caused by their unspecific presentation of acute neonatal encephalopathy with high early mortality, followed by the evolution of dystonic cerebral palsy and also by the lack of easily available and reliable diagnostic tests. There is significant variation in survival and in the quality of symptomatic management of affected children. One of the four disorders, molybdenum cofactor deficiency type A (MoCD-A) has recently become amenable to causal treatment with synthetic cPMP (fosdenopterin). The evidence base for the rational use of cPMP is very limited. This prompted the formulation of these clinical guidelines to facilitate diagnosis and support the management of patients. The guidelines were developed by experts in diagnosis and treatment of sulfite intoxication disorders. It reflects expert consensus opinion and evidence from a systematic literature search.
Asunto(s)
Errores Innatos del Metabolismo de los Metales , Sulfito-Oxidasa , Humanos , Recién Nacido , Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Errores Innatos del Metabolismo de los Aminoácidos/terapia , Errores Innatos del Metabolismo de los Aminoácidos/genética , Coenzimas/deficiencia , Consenso , Errores Innatos del Metabolismo de los Metales/diagnóstico , Errores Innatos del Metabolismo de los Metales/terapia , Metaloproteínas/deficiencia , Cofactores de Molibdeno , Pteridinas , Sulfito-Oxidasa/deficiencia , Sulfito-Oxidasa/genéticaRESUMEN
The molybdenum cofactor (Moco) is a 520-Da prosthetic group that is synthesized in all domains of life. In animals, four oxidases (among them sulfite oxidase) use Moco as a prosthetic group. Moco is essential in animals; humans with mutations in genes that encode Moco biosynthetic enzymes display lethal neurological and developmental defects. Moco supplementation seems a logical therapy; however, the instability of Moco has precluded biochemical and cell biological studies of Moco transport and bioavailability. The nematode Caenorhabditis elegans can take up Moco from its bacterial diet and transport it to cells and tissues that express Moco-requiring enzymes, suggesting a system for Moco uptake and distribution. Here we show that protein-bound Moco is the stable, bioavailable species of Moco taken up by C. elegans from its diet and is an effective dietary supplement, rescuing a Celegans model of Moco deficiency. We demonstrate that diverse Moco:protein complexes are stable and bioavailable, suggesting a new strategy for the production and delivery of therapeutically active Moco to treat human Moco deficiency.
Asunto(s)
Caenorhabditis elegans/metabolismo , Coenzimas/administración & dosificación , Errores Innatos del Metabolismo de los Metales/terapia , Metaloproteínas/administración & dosificación , Pteridinas/administración & dosificación , Animales , Bacterias/metabolismo , Transporte Biológico , Coenzimas/deficiencia , Coenzimas/farmacocinética , Humanos , Metaloproteínas/deficiencia , Metaloproteínas/farmacocinética , Cofactores de Molibdeno , Unión Proteica , Pteridinas/farmacocinéticaRESUMEN
Copper is an essential cofactor of cytochrome c oxidase (CcO), the terminal enzyme of the mitochondrial respiratory chain. Inherited loss-of-function mutations in several genes encoding proteins required for copper delivery to CcO result in diminished CcO activity and severe pathologic conditions in affected infants. Copper supplementation restores CcO function in patient cells with mutations in two of these genes, COA6 and SCO2, suggesting a potential therapeutic approach. However, direct copper supplementation has not been therapeutically effective in human patients, underscoring the need to identify highly efficient copper transporting pharmacological agents. By using a candidate-based approach, we identified an investigational anticancer drug, elesclomol (ES), that rescues respiratory defects of COA6-deficient yeast cells by increasing mitochondrial copper content and restoring CcO activity. ES also rescues respiratory defects in other yeast mutants of copper metabolism, suggesting a broader applicability. Low nanomolar concentrations of ES reinstate copper-containing subunits of CcO in a zebrafish model of copper deficiency and in a series of copper-deficient mammalian cells, including those derived from a patient with SCO2 mutations. These findings reveal that ES can restore intracellular copper homeostasis by mimicking the function of missing transporters and chaperones of copper, and may have potential in treating human disorders of copper metabolism.
Asunto(s)
Antineoplásicos/farmacología , Cobre/deficiencia , Drogas en Investigación/farmacología , Complejo IV de Transporte de Electrones/metabolismo , Hidrazinas/farmacología , Mitocondrias/efectos de los fármacos , Animales , Antineoplásicos/uso terapéutico , Transporte Biológico/genética , Proteínas Portadoras/genética , Línea Celular , Coenzimas/deficiencia , Cobre/uso terapéutico , Transportador de Cobre 1 , Suplementos Dietéticos , Modelos Animales de Enfermedad , Reposicionamiento de Medicamentos , Drogas en Investigación/uso terapéutico , Fibroblastos , Humanos , Hidrazinas/uso terapéutico , Proteínas de Transporte de Membrana/genética , Errores Innatos del Metabolismo/tratamiento farmacológico , Errores Innatos del Metabolismo/genética , Errores Innatos del Metabolismo/metabolismo , Mitocondrias/metabolismo , Proteínas Mitocondriales/genética , Chaperonas Moleculares , Mutagénesis Sitio-Dirigida , Mutación , Ratas , Saccharomyces cerevisiae , Pez Cebra , Proteínas de Pez Cebra/genéticaRESUMEN
AIM: Molybdenum co-factor deficiencies and isolated sulfite oxidase deficiency are rare autosomal recessively inherited diseases characterized by severe psychomotor impairment, intractable seizures, dislocated lens and dysmorphic facial features. The biochemical diagnosis of these diseases requires the determination of urine sulfocysteine. MATERIALS & METHODS: Urine sulfocysteine was quantified by an ultra-high performance liquid chromatography-MS/MS assay. The method was validated for linearity, accuracy, precision, recovery and stability. RESULTS & CONCLUSION: Total imprecision of accuracy was less than 6%. Intra-assay and inter-assay precisions were less than 5%. The recovery was higher than 98%. The method is inexpensive, fast, accurate and has been successfully used for identifying five molybdenum co-factor deficient and six sulfite oxidase deficient patients since deployed.
Asunto(s)
Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Errores Innatos del Metabolismo de los Aminoácidos/orina , Cisteína/análogos & derivados , Molibdeno/deficiencia , Sulfito-Oxidasa/deficiencia , Urinálisis/métodos , Cromatografía Líquida de Alta Presión , Coenzimas/deficiencia , Cisteína/orina , Humanos , Límite de Detección , Modelos Lineales , Sulfito-Oxidasa/orina , Espectrometría de Masas en Tándem , Factores de TiempoRESUMEN
Inborn errors of metabolism (IEM) are relatively uncommon causes for seizures in children; however, they should be considered in the differential diagnosis because several IEM are potentially treatable and seizures can be resolved if appropriate treatment is initiated. Clues from clinical presentation, physical examination, laboratory tests, and brain imaging can raise the possibility of IEM. Several IEM can present with seizures, either as the main presenting finding or as a part of a more complex phenotype. These include cofactor-related disorders, glycine and serine metabolism defects, and other disorders.
Asunto(s)
Epilepsia/etiología , Errores Innatos del Metabolismo/diagnóstico , Niño , Preescolar , Coenzimas/deficiencia , Diagnóstico Diferencial , Epilepsia/terapia , Glicina/metabolismo , Humanos , Lactante , Recién Nacido , Errores Innatos del Metabolismo/terapia , Serina/metabolismoRESUMEN
Immunoactivation depends upon the antigen potential to modulate T-cell repertoires. The present study has enumerated the effect of 61 kDa recombinant Leishmania donovani co-factor-independent phosphoglycerate mutase (rLd-iPGAM) on mononuclear cells of healthy and treated visceral leishmaniasis subjects as well as on THP-1 cell line. rLd-iPGAM stimulation induced higher expression of interleukin-1ß (IL-1ß) in the phagocytic cell, its receptor and CD69 on T-cell subsets. These cellular activations resulted in upregulation of host-protective cytokines IL-2, IL-12, IL-17, tumour necrosis factor-α and interferon-γ, and downregulation of IL-4, IL-10 and tumour growth factor-ß. This immune polarization was also evidenced by upregulation of nuclear factor-κ light-chain enhancer of activated B cells p50 and regulated expression of suppressor of mother against decapentaplegic protein-4. rLd-iPGAM stimulation also promoted lymphocyte proliferation and boosted the leishmaniacidal activity of macrophages by upregulating reactive oxygen species. It also induced 1·8-fold higher release of nitric oxide (NO) by promoting the transcription of inducible nitric oxide synthase gene. Besides, in silico analysis suggested the presence of major histocompatibility complex class I and II restricted epitopes, which can proficiently trigger CD8+ and CD4+ cells, respectively. This study reports rLd-iPGAM as an effective immunoprophylactic agent, which can be used in future vaccine design.
Asunto(s)
Epítopos de Linfocito T/inmunología , Leishmania donovani/enzimología , Leishmania donovani/inmunología , Macrófagos/inmunología , Fosfoglicerato Mutasa/inmunología , Proteínas Recombinantes/farmacología , Línea Celular , Coenzimas/deficiencia , Coenzimas/genética , Simulación por Computador , Citocinas/efectos de los fármacos , Citocinas/inmunología , Epítopos de Linfocito T/efectos de los fármacos , Genes MHC Clase I/inmunología , Genes MHC Clase II/inmunología , Humanos , Interleucina-1beta/efectos de los fármacos , Interleucina-1beta/inmunología , Leishmaniasis Visceral/inmunología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Leucocitos Mononucleares/parasitología , Activación de Linfocitos/efectos de los fármacos , Macrófagos/parasitología , Subunidad p50 de NF-kappa B/efectos de los fármacos , Subunidad p50 de NF-kappa B/genética , Óxido Nítrico , Óxido Nítrico Sintasa de Tipo II/efectos de los fármacos , Fosfoglicerato Mutasa/genética , Fosfoglicerato Mutasa/farmacología , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Células TH1RESUMEN
INTRODUCTION: Individually, neurometabolic diseases are ultra rare, but for some of them there is an effective treatment. DEVELOPMENT: Several recent therapeutic advances are reviewed. Today, the possibilities of treatment for lysosomal diseases have improved. In recent years the use of enzyme replacement therapy has become more widely extended to treat mucopolysaccharidosis type IVA (Morquio A), mucopolysaccharidosis type VII (Sly syndrome), lysosomal acid lipase deficiency and alpha-mannosidosis. It has been proven that very early treatment of mucopolysaccharidoses can change their natural course. Intrathecal enzyme replacement therapy is being tried in some mucopolysaccharidoses with cognitive involvement, in an attempt to halt neurodegeneration. Very positive results have been obtained with genetically modified autotransplants in late-onset infantile metachromatic leukodystrophy and research is being conducted on other pathologies (mucopolysaccharidosis type III, X-linked adrenoleukodystrophy). Novel outcomes are also being achieved in the treatment of some encephalopathies that are sensitive to vitamins or cofactors: triple therapy in pyridoxine dependency, treatment with thiamine for some subacute encephalopathies with involvement of the basal ganglia, treatment with folinic acid for children with cerebral folate deficiency, or treatment with cyclic pyranopterin monophosphate in molybdenum cofactor deficiency type A. CONCLUSIONS: As neuropaediatricians we must update our knowledge, especially in the case of treatable neurometabolic pathologies, since early treatment can change their prognosis significantly.
TITLE: Terapias novedosas en enfermedades neurometabolicas: importancia de una intervencion precoz.Introduccion. Las enfermedades neurometabolicas son individualmente ultrarraras, pero algunas de ellas tienen un tratamiento eficaz. Desarrollo. Se revisan algunas novedades terapeuticas. Las enfermedades lisosomales tienen actualmente mejores posibilidades de tratamiento. En los ultimos años se ha extendido el uso de la terapia enzimatica sustitutiva a la mucopolisacaridosis tipo IVA (Morquio A), a la mucopolisacaridosis tipo VII (enfermedad de Sly), al deficit de lipasa acida lisosomal y a la alfa-manosidosis. Se ha constatado que un tratamiento muy precoz de las mucopolisacaridosis puede cambiar su historia natural. Se esta probando la terapia enzimatica sustitutiva intratecal en algunas mucopolisacaridosis con afectacion cognitiva, en el intento de frenar la neurodegeneracion. Se han obtenido resultados muy positivos con autotrasplante modificado geneticamente en leucodistrofia metacromatica infantil tardia y se esta trabajando en otras patologias (mucopolisacaridosis tipo III, adrenoleucodistrofia ligada a X). Tambien hay novedades en la terapia de algunas encefalopatias sensibles a vitaminas o cofactores: la triple terapia en la dependencia de piridoxina, el tratamiento con tiamina de algunas encefalopatias subagudas con afectacion de ganglios basales, el tratamiento con acido folinico de niños con deficiencia de folato cerebral, o el tratamiento con monofosfato de piranopterina ciclico en los defectos de cofactor de molibdeno de tipo A. Conclusiones. Los neuropediatras debemos actualizar nuestro conocimiento especialmente en aquellas patologias neurometabolicas tratables, dado que una terapia precoz puede cambiar de forma significativa su pronostico.
Asunto(s)
Encefalopatías Metabólicas Innatas/terapia , Intervención Médica Temprana , Enfermedades del Sistema Nervioso/terapia , Terapias en Investigación , Avitaminosis/terapia , Encefalopatías Metabólicas Innatas/diagnóstico , Encefalopatías Metabólicas Innatas/genética , Proteínas Portadoras/metabolismo , Niño , Ensayos Clínicos como Asunto , Coenzimas/deficiencia , Coenzimas/uso terapéutico , Diagnóstico Precoz , Terapia de Reemplazo Enzimático , Epilepsia/genética , Epilepsia/metabolismo , Epilepsia/terapia , Terapia Genética , Humanos , Recién Nacido , Enfermedades por Almacenamiento Lisosomal del Sistema Nervioso/tratamiento farmacológico , Enfermedades por Almacenamiento Lisosomal del Sistema Nervioso/genética , Enfermedades del Sistema Nervioso/diagnósticoRESUMEN
Primary adrenal insufficiency (PAI) is potentially life threatening, but rare. In children, genetic defects prevail whereas adults suffer more often from acquired forms of PAI. The spectrum of genetic defects has increased in recent years with the use of next-generation sequencing methods and now has reached far beyond genetic defects in all known enzymes of adrenal steroidogenesis. Cofactor disorders such as P450 oxidoreductase (POR) deficiency manifesting as a complex form of congenital adrenal hyperplasia with a broad clinical phenotype have come to the fore. In patients with isolated familial glucocorticoid deficiency (FGD), in which no mutations in the genes for the ACTH receptor (MC2R) or its accessory protein MRAP have been found, non-classic steroidogenic acute regulatory protein (StAR) and CYP11A1 mutations have been described; and more recently novel mutations in genes such as nicotinamide nucleotide transhydrogenase (NNT) and thioredoxin reductase 2 (TRXR2) involved in the maintenance of the mitochondrial redox potential and generation of NADPH important for steroidogenesis and ROS detoxication have been discovered. In addition, whole exome sequencing approach also solved the genetics of some syndromic forms of PAI including IMAGe syndrome (CDKN1C), Irish traveler syndrome (MCM4), MIRAGE syndrome (SAMD9); and most recently a syndrome combining FGD with steroid-resistant nephrotic syndrome and ichthyosis caused by mutations in the gene for sphingosine-1-phosphate lyase 1 (SGPL1). This review intends do give an update on novel genetic forms of PAI and their suggested mechanism of disease. It also advocates for advanced genetic work-up of PAI (especially in children) to reach a specific diagnosis for better counseling and treatment.
Asunto(s)
Enfermedad de Addison/enzimología , Enfermedad de Addison/inmunología , Coenzimas/deficiencia , Estrés Oxidativo/fisiología , Enfermedad de Addison/genética , Corteza Suprarrenal/enzimología , Corteza Suprarrenal/inmunología , Enfermedades Autoinmunes/enzimología , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/inmunología , Coenzimas/genética , HumanosRESUMEN
Protein biogenesis is tightly linked to protein quality control (PQC). The role of PQC machinery in recognizing faulty polypeptides is becoming increasingly understood. Molecular chaperones and cytosolic and vacuolar degradation systems collaborate to detect, repair, or hydrolyze mutant, damaged, and mislocalized proteins. On the other hand, the contribution of PQC to cofactor binding-related enzyme maturation remains largely unexplored, although the loading of a cofactor represents an all-or-nothing transition in regard to the enzymatic function and thus must be surveyed carefully. Combining proteomics and biochemical analysis, we demonstrate here that cells are able to detect functionally immature wild-type enzymes. We show that PQC-dedicated ubiquitin ligase C-terminal Hsp70-interacting protein (CHIP) recognizes and marks for degradation not only a mutant protein but also its wild-type variant as long as the latter remains cofactor free. A distinct structural feature, the protruding C-terminal tail, which appears in both the mutant and wild-type polypeptides, contributes to recognition by CHIP. Our data suggest that relative insufficiency of apoprotein degradation caused by cofactor shortage can increase amyloidogenesis and aggravate protein aggregation disorders.
Asunto(s)
Coenzimas/deficiencia , Flavoproteínas/química , Proteínas HSP70 de Choque Térmico/metabolismo , NAD(P)H Deshidrogenasa (Quinona)/química , Riboflavina/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Animales , Coenzimas/química , Flavoproteínas/genética , Flavoproteínas/metabolismo , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Proteínas HSP70 de Choque Térmico/genética , Melanoma Experimental , Ratones , Modelos Moleculares , NAD/química , NAD/metabolismo , NAD(P)H Deshidrogenasa (Quinona)/genética , NAD(P)H Deshidrogenasa (Quinona)/metabolismo , Agregado de Proteínas , Estructura Secundaria de Proteína , Proteolisis , Proteoma/genética , Proteoma/metabolismo , Proteómica/métodos , Fosfato de Piridoxal/química , Fosfato de Piridoxal/metabolismo , Riboflavina/química , Tiamina Pirofosfato/química , Tiamina Pirofosfato/metabolismo , Células Tumorales Cultivadas , Ubiquitina-Proteína Ligasas/genéticaRESUMEN
Uric acid accumulates in the epidermis of Bombyx mori larvae and renders the larval integument opaque and white. Yamamoto translucent (oya) is a novel spontaneous mutant with a translucent larval integument and unique phenotypic characteristics, such as male-biased lethality and flaccid larval paralysis. Xanthine dehydrogenase (XDH) that requires a molybdenum cofactor (MoCo) for its activity is a key enzyme for uric acid synthesis. It has been observed that injection of a bovine xanthine oxidase, which corresponds functionally to XDH and contains its own MoCo activity, changes the integuments of oya mutants from translucent to opaque and white. This finding suggests that XDH/MoCo activity might be defective in oya mutants. Our linkage analysis identified an association between the oya locus and chromosome 23. Because XDH is not linked to chromosome 23 in B. mori, MoCo appears to be defective in oya mutants. In eukaryotes, MoCo is synthesized by a conserved biosynthesis pathway governed by four loci (MOCS1, MOCS2, MOCS3, and GEPH). Through a candidate gene approach followed by sequence analysis, a 6-bp deletion was detected in an exon of the B. mori molybdenum cofactor synthesis-step 1 gene (BmMOCS1) in the oya strain. Moreover, recombination was not observed between the oya and BmMOCS1 loci. These results indicate that the BmMOCS1 locus is responsible for the oya locus. Finally, we discuss the potential cause of male-biased lethality and flaccid paralysis observed in the oya mutants.
Asunto(s)
Bombyx/fisiología , Coenzimas/genética , Proteínas de Insectos/genética , Metaloproteínas/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Bombyx/genética , Bombyx/crecimiento & desarrollo , Clonación Molecular , Coenzimas/química , Coenzimas/deficiencia , Dioxigenasas/genética , Dioxigenasas/metabolismo , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Proteínas de Insectos/química , Proteínas de Insectos/deficiencia , Larva/genética , Larva/crecimiento & desarrollo , Larva/fisiología , Masculino , Metaloproteínas/química , Metaloproteínas/deficiencia , Cofactores de Molibdeno , Pteridinas/químicaRESUMEN
Human development and its physiology depends on a number of complex biochemical body processes, many of which are interactive and codependent. The speed and the degree in which many physiological reactions are completed depend on enzyme activity, which in turn depends on the bioavailability of co-factors and micronutrients such as vitamins and minerals. To achieve a healthy physiological state, organism need that biochemical reactions occur in a controlled and specific way at a particular speed and level or grade fully completed. To achieve this, is required an optimal metabolic balance. Factors such as, a particular genetic composition, inadequate dietary consumption patterns, traumas, diseases, toxins and environmental stress all of these factors rising demands for nutrients in order to obtain optimal metabolic balance. Metabolic correction is a biochemical and physiological concept that explains how improvements in cellular biochemistry of an organism can help the body achieve metabolic and physiological optimization. We summarize the contribution of several pioneers in understanding the role of micronutrients in health management. The concept of metabolic correction is becoming a significant term due to the presence of genetic variants that affect the speed of reactions of enzymes, causing metabolic alterations that enhance or promote the state/development of multiple diseases. Decline in the nutritional value of the food we eat, the increase in demand for certain nutrients caused by normal development, diseases and medications induce, usually, nutrients consumption. These nutritional deficiencies and insufficiencies are causing massive economic costs due to increased morbidity and mortality in our society. In summary, metabolic correction improves the enzymatic function, which favors the physiological normal functions, thus, contributing to improving health and the welfare of the human being. The purpose of this paper is to describe and introduce the concept of optimal metabolic correction as a functional cost-effective mechanism against disease, in addition, to contribute to diseases prevention and regeneration of the body and health.
Asunto(s)
Micronutrientes/fisiología , Prevención Primaria/métodos , Avitaminosis/complicaciones , Avitaminosis/terapia , Coenzimas/deficiencia , Coenzimas/fisiología , Coenzimas/uso terapéutico , Daño del ADN , Suplementos Dietéticos , Metabolismo Energético , Enzimas/fisiología , Conducta Alimentaria , Humanos , Desnutrición/complicaciones , Desnutrición/terapia , Micronutrientes/deficiencia , Micronutrientes/uso terapéutico , Minerales/uso terapéutico , Modelos Biológicos , Necesidades Nutricionales , Medicina de Precisión , Estados Unidos , Vitaminas/uso terapéuticoRESUMEN
Analysis of α-aminoadipic semialdehyde is an important tool in the diagnosis of antiquitin deficiency (pyridoxine-dependent epilepsy). However continuing use of this test has revealed that elevated urinary excretion of α-aminoadipic semialdehyde is not only found in patients with pyridoxine-dependent epilepsy but is also seen in patients with molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. This should be taken into account when interpreting the laboratory data. Sulphite was shown to inhibit α-aminoadipic semialdehyde dehydrogenase in vitro.
Asunto(s)
Ácido 2-Aminoadípico/análogos & derivados , Errores Innatos del Metabolismo de los Aminoácidos/orina , Coenzimas/deficiencia , Errores Innatos del Metabolismo de los Metales/orina , Metaloproteínas/deficiencia , Oxidorreductasas actuantes sobre Donantes de Grupos Sulfuro/deficiencia , Ácido 2-Aminoadípico/orina , Adolescente , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Niño , Cisteína/análogos & derivados , Cisteína/farmacología , Humanos , Recién Nacido , L-Aminoadipato-Semialdehído Deshidrogenasa/antagonistas & inhibidores , Lisina/metabolismo , Redes y Vías Metabólicas , Errores Innatos del Metabolismo de los Metales/metabolismo , Modelos Biológicos , Cofactores de Molibdeno , Molibdoferredoxina/metabolismo , Molibdoferredoxina/orina , Pteridinas , Sulfito-Oxidasa/deficiencia , Sulfito-Oxidasa/metabolismo , Sulfito-Oxidasa/orina , Sulfitos/farmacologíaRESUMEN
Molybdenum cofactor (Moco) deficiency is a rare neurometabolic disorder, characterized by neurological impairment and refractive seizures, due to toxic accumulation of sulfite in the brain. Earlier it was suggested that in Moco-deficient humans maternal clearance of neurotoxic metabolites prevents prenatal brain damage. However, limited data are available about the time profile in which neurophysiologic deterioration occurs after birth. The amplitude-integrated electroencephalography (aEEG) is a bedside method in neonates to monitor cerebral recovery after hypoxic-ischemic insults, detect epileptic activity, and evaluate antiepileptic drug treatment. We describe a chronological series of changes in aEEG tracings in a neonate with Moco deficiency. He presented with myoclonic spasms and hypertonicity a few hours after birth, however, the aEEG pattern was still normal. Within 2 days, the aEEG rapidly changed into a burst suppression pattern with repetitive seizures. After antiepileptic treatment, the aEEG remained abnormal. In this patient, the normal aEEG pattern at birth may have been due to maternal clearance of sulfite in utero. After birth, accumulation of sulfite causes progressive brain damage, reflected by the progressive depression of the aEEG tracings. This is in agreement with the results from a Moco-deficient mouse model, suggesting that maternal sulfite clearance suppresses prenatal brain damage. To our knowledge, this is the first case report describing the chronological changes in the aEEG pattern in a Moco-deficient patient. Insight into the time profile in which neurologic deterioration in Moco-deficient humans occurs is essential, especially when potential treatment strategies are being evaluated.
Asunto(s)
Ondas Encefálicas , Encéfalo/fisiopatología , Coenzimas/deficiencia , Electroencefalografía , Epilepsia/diagnóstico , Errores Innatos del Metabolismo de los Metales/diagnóstico , Metaloproteínas/deficiencia , Anticonvulsivantes/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Ondas Encefálicas/efectos de los fármacos , Coenzimas/genética , Imagen de Difusión por Resonancia Magnética , Epilepsia/tratamiento farmacológico , Epilepsia/enzimología , Epilepsia/fisiopatología , Humanos , Recién Nacido , Masculino , Errores Innatos del Metabolismo de los Metales/enzimología , Errores Innatos del Metabolismo de los Metales/genética , Errores Innatos del Metabolismo de los Metales/fisiopatología , Metaloproteínas/genética , Cofactores de Molibdeno , Molibdoferredoxina/genética , Valor Predictivo de las Pruebas , Pteridinas , Sulfitos/metabolismo , Factores de Tiempo , Resultado del TratamientoRESUMEN
Molybdenum cofactor (MoCo) deficiency is a rare autosomal recessive inherited metabolic disorder resulting in the combined deficiency of aldehyde oxidase, xanthine dehydrogenase, and sulfite oxidase. We report a male infant with MoCo deficiency whose clinical findings consisted of microcephaly, intractable seizures soon after birth, feeding difficulties, and developmental delay. Sequencing of MOCS1, MOCS2, and GEPH genes, and single nucleotide polymorphism genotyping array analysis showed, to our knowledge, unusual inheritance of MoCo deficiency/maternal uniparental isodisomy for the first time in the literature. At 10 months of age, he now has microcephaly and developmental delay, and his seizures are controlled with phenobarbital, clonozepam, and vigabatrin therapy.
Asunto(s)
Coenzimas/deficiencia , Errores Innatos del Metabolismo/genética , Metaloproteínas/deficiencia , Madres , Disomía Uniparental , Liasas de Carbono-Carbono , Proteínas Portadoras/genética , Discapacidades del Desarrollo/genética , Conducta Alimentaria , Femenino , Humanos , Lactante , Masculino , Proteínas de la Membrana/genética , Microcefalia/genética , Cofactores de Molibdeno , Proteínas Nucleares/genética , Polimorfismo de Nucleótido Simple , Pteridinas , Convulsiones/tratamiento farmacológico , Convulsiones/genética , Sulfurtransferasas/genéticaRESUMEN
Molybdenum cofactor deficiency (MoCD) is a rare metabolic disorder characterized by severe and rapidly progressive neurologic damage caused by the functional loss of sulfite oxidase, 1 of 4 molybdenum-dependent enzymes. To date, no effective therapy is available for MoCD, and death in early infancy has been the usual outcome. We report here the case of a patient who was diagnosed with MoCD at the age of 6 days. Substitution therapy with purified cyclic pyranopterin monophosphate (cPMP) was started on day 36 by daily intravenous administration of 80 to 160 microg of cPMP/kg of body weight. Within 1 to 2 weeks, all urinary markers of sulfite oxidase (sulfite, S-sulfocysteine, thiosulfate) and xanthine oxidase deficiency (xanthine, uric acid) returned to almost normal readings and stayed constant (>450 days of treatment). Clinically, the infant became more alert, convulsions and twitching disappeared within the first 2 weeks, and an electroencephalogram showed the return of rhythmic elements and markedly reduced epileptiform discharges. Substitution of cPMP represents the first causative therapy available for patients with MoCD. We demonstrate efficient uptake of cPMP and restoration of molybdenum cofactor-dependent enzyme activities. Further neurodegeneration by toxic metabolites was stopped in the reported patient. We also demonstrated the feasibility to detect MoCD in newborn-screening cards to enable early diagnosis.
Asunto(s)
Encefalopatías Metabólicas Innatas/tratamiento farmacológico , Coenzimas/deficiencia , Metaloproteínas/deficiencia , Pterinas/administración & dosificación , Errores Innatos del Metabolismo de la Purina-Pirimidina/tratamiento farmacológico , Sulfito-Oxidasa/deficiencia , Encefalopatías Metabólicas Innatas/diagnóstico , Diagnóstico Diferencial , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Recién Nacido , Infusiones Intravenosas , Cofactores de Molibdeno , Compuestos Organofosforados/uso terapéutico , Pteridinas , Pterinas/uso terapéutico , Errores Innatos del Metabolismo de la Purina-Pirimidina/diagnósticoRESUMEN
Sulfite oxidase is a mitochondrial enzyme encoded by the SUOX gene and essential for the detoxification of sulfite which results mainly from the catabolism of sulfur-containing amino acids. Decreased activity of this enzyme can either be due to mutations in the SUOX gene or secondary to defects in the synthesis of its cofactor, the molybdenum cofactor. Defects in the synthesis of the molybdenum cofactor are caused by mutations in one of the genes MOCS1, MOCS2, MOCS3 and GEPH and result in combined deficiencies of the enzymes sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase. Although present in many ethnic groups, isolated sulfite oxidase deficiency and molybdenum cofactor deficiency are rare inborn errors of metabolism, which makes awareness of key clinical and laboratory features of affected individuals crucial for early diagnosis. We report clinical, radiologic, biochemical and genetic data on a Brazilian and on a Turkish child with sulfite oxidase deficiency due to the isolated defect and impaired synthesis of the molybdenum cofactor, respectively. Both patients presented with early onset seizures and neurological deterioration. They showed no sulfite oxidase activity in fibroblasts and were homozygous for the mutations c.1136A>G in the SUOX gene and c.667insCGA in the MOCS1 gene, respectively. Widely available routine laboratory tests such as assessment of total homocysteine and uric acid are indicated in children with a clinical presentation resembling that of hypoxic ischemic encephalopathy and may help in obtaining a tentative diagnosis locally, which requires confirmation by specialized laboratories.
Asunto(s)
Coenzimas/deficiencia , Encefalomalacia/enzimología , Encefalomalacia/patología , Enfermedades del Recién Nacido/enzimología , Enfermedades del Recién Nacido/etiología , Metaloproteínas/deficiencia , Convulsiones/etiología , Sulfito-Oxidasa/deficiencia , Errores Innatos del Metabolismo de los Aminoácidos/complicaciones , Errores Innatos del Metabolismo de los Aminoácidos/genética , Brasil , Coenzimas/genética , Análisis Mutacional de ADN , Diagnóstico Diferencial , Encefalomalacia/etiología , Encefalomalacia/genética , Femenino , Humanos , Recién Nacido , Enfermedades del Recién Nacido/genética , Enfermedades del Recién Nacido/patología , Metaloproteínas/genética , Cofactores de Molibdeno , Pteridinas , Convulsiones/complicaciones , Sulfito-Oxidasa/genética , TurquíaRESUMEN
Molybdenum cofactor deficiency is a rare autosomal recessive disorder with devastating neurological manifestations, characterised by neonatal-onset encephalopathy mimicking hypoxic-ischaemic insult, intractable seizure, and feeding and respiratory difficulties. It is often fatal in the early life. We report an affected 8-year-old boy, who presented with severe neurological manifestations since birth, but without clinically-significant seizure. Molybdenum cofactor deficiency must be included in the differential diagnosis of patients presenting with unexplained encephalopathy in the newborn period, and whose neuroimaging findings are consistent with hypoxic ischaemic encephalopathy. The classic laboratory hallmark of this disorder is low serum uric acid, positive urine sulphite dipstick test, and elevated urinary S-sulphocysteine, hypoxanthine and xanthine.
Asunto(s)
Coenzimas/deficiencia , Metaloproteínas/deficiencia , Encefalopatías/patología , Niño , Cisteína/análogos & derivados , Cisteína/sangre , Diagnóstico Diferencial , Humanos , Hipoxantina/metabolismo , Hipoxia/patología , Isquemia/patología , Malasia , Masculino , Cofactores de Molibdeno , Pteridinas , Sulfitos/orina , Ácido Úrico/metabolismo , Xantina/metabolismoRESUMEN
The trace element molybdenum is essential for nearly all organisms and forms the catalytic centre of a large variety of enzymes such as nitrogenase, nitrate reductases, sulphite oxidase and xanthine oxidoreductases. Nature has developed two scaffolds holding molybdenum in place, the iron-molybdenum cofactor and pterin-based molybdenum cofactors. Despite the different structures and functions of molybdenum-dependent enzymes, there are important similarities, which we highlight here. The biosynthetic pathways leading to both types of cofactor have common mechanistic aspects relating to scaffold formation, metal activation and cofactor insertion into apoenzymes, and have served as an evolutionary 'toolbox' to mediate additional cellular functions in eukaryotic metabolism.
Asunto(s)
Coenzimas/metabolismo , Enzimas/metabolismo , Metaloproteínas/metabolismo , Pteridinas/metabolismo , Animales , Coenzimas/deficiencia , Cobre/metabolismo , Humanos , Hierro/metabolismo , Metaloproteínas/deficiencia , Cofactores de Molibdeno , Nucleótidos/metabolismo , Pterinas/metabolismoRESUMEN
Molybdenum cofactor deficiency (MOCOD) is a rare inherited metabolic disorder resulting in the combined deficiency of aldehyde oxidase (AO, EC 1.2.3.1), xanthine dehydrogenase (XDH, EC 1.1.1.204), and sulfite oxidase (SUOX, EC 1.8.3.1). The majority of patients typically present soon after birth with intractable seizures, developmental delay and lens dislocation and do not survive early childhood. Milder cases have been reported. We report an unusual mutation in the MOCS1 gene associated with a relatively mild clinical phenotype, in a patient who presented with normal uric acid (UA) levels in plasma. We also report a new MOCS1 mRNA splice variant in the 5' region of the gene. MOCS1 genomic DNA and cDNA from peripheral blood leukocytes were sequenced. MOCS1 mRNA splice variants were amplified with fluorescently labelled primers and quantitated. A novel homozygous mutation MOCS1c.1165+6T > C in intron 9 resulting in miss-splicing of exon 9 was found. Multiple alternatively spliced MOCS1 transcripts have been previously reported. A new MOCS1 transcript in the 5' - exon 1 region was identified in both patient and controls. This new transcript derived from the Larin variant and lacked exon 1 d.
Asunto(s)
Empalme Alternativo/genética , Coenzimas/deficiencia , Errores Innatos del Metabolismo/genética , Metaloproteínas/deficiencia , Proteínas Nucleares/genética , Secuencia de Bases , Liasas de Carbono-Carbono , Niño , Coenzimas/genética , Análisis Mutacional de ADN , Exones/genética , Humanos , Masculino , Metaloproteínas/genética , Modelos Biológicos , Datos de Secuencia Molecular , Cofactores de Molibdeno , Polimorfismo Genético/fisiología , PteridinasRESUMEN
Copper (Cu) is essential for proper brain development, particularly the cerebellum, and functions as a cofactor for enzymes including mitochondrial cytochrome c oxidase (CCO). Cu deficiency severely limits CCO activity. Augmented lactate in brain of Cu deficient (Cu-) humans and cerebella of Cu- rats is though to originate from impaired mitochondria. However, brain lactate may also originate from elevated blood lactate. The hypothesis that cerebellar lactate originates from elevated blood lactate in Cu- rat pups was tested. Analysis of Cu- and Cu adequate (Cu+) rat pups (experiment I) revealed blood lactate was elevated in Cu- rat pups and cerebellar lactate levels were closely correlated to blood lactate concentration. A second rat experiment (experiment II) assessed Cu- cerebellar lactate without the confounding factor of elevated blood lactate. Blood lactate levels of Cu- rat pups in experiment II were equal to those of controls; however, Cu- cerebellar lactate was still elevated, suggesting mitochondrial impairment by Cu deficiency. Treatment of rat pups with dichloroacetate (DCA), an activator of mitochondrial pyruvate dehydrogenase complex (PDC), lowered Cu- cerebellar lactate to control levels suggesting PDC inhibition is a site of mitochondrial impairment in Cu- cerebella. Results suggest Cu- cerebellar lactate originates from blood and cerebellum.